<DOC>
	<DOC>NCT01439958</DOC>
	<brief_summary>The purpose of this study is to evaluate long-term safety of L-CsA in prevention of bronchiolitis obliterans syndrome (BOS) following lung transplantation (LTx) in patients previously enrolled in phase II/III L-CsA clinical trial 12011.201.</brief_summary>
	<brief_title>Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS)</brief_title>
	<detailed_description>This is an uncontrolled extension study open only to patients who completed the Phase II/III core study 12011.201 and volunteered to continue or to cross-over to L-CsA inhalation therapy. Determination of long-term safety and efficacy outcome over a maximum of three years will be assessed.</detailed_description>
	<mesh_term>Bronchiolitis</mesh_term>
	<mesh_term>Bronchiolitis Obliterans</mesh_term>
	<criteria>1. Patient has completed the LCsA clinical trial 12011.201 2. Patient is capable of understanding the purpose and risks of the followup study, has been fully informed and has given written informed consent to participate in the study 3. Female patients of child bearing potential must test negative on standard urine pregnancy test prior to continuation and must agree to practice effective birth control during the study 4. Estimated life expectancy &gt; 6 months 5. Capable of selfadministration of medications 6. Patient has stable creatinine levels 1. Patients with ongoing irreversible LCsA related serious adverse events 2. Patients with known hypersensitivity for ciclosporin A 3. Patient intends to participate in another IMP clinical trial other than listed in the inclusion criteria 4. Patient receives mechanical ventilation 5. Patients underwent pulmonary retransplantation 6. Patient is a pregnant or breastfeeding woman 7. Patient is unlikely to comply with visits, inhalation procedures or spirometric measurements scheduled in the protocol 8. Patient receives any systemic or topical Rosuvastatin 9. Patient has been previously enrolled in this study 10. Patient with malignancy diagnosed during study 12011.201 (with the exception of skin cancer) 11. Documented respiratory infections unless on appropriate antimicrobial therapy with evidence of clinical response 12. Patient is not eligible to continue IMP inhalation according to the Investigator's discretion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Inhalation</keyword>
	<keyword>Lung Transplantation</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>